Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Next Previous
Drug Profile

Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Alternative Names: Anti-N2 monoclonal antibody - DecImmune Therapeutics; Anti-N2F(ab')2 MAb; Antibody 21G6 - DecImmune Therapeutics; DeciMab; N2 inhibitors - DecImmune Therapeutics; Non-muscle myosin heavy-chain II inhibitors - DecImmune Therapeutics; Synthetic N2 peptide - DecImmune Therapeutics

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DecImmune Therapeutics
  • Class Antibodies; Monoclonal antibodies; Peptides
  • Mechanism of Action Inflammation mediator inhibitors; Myosin type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial ischaemia; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-ischaemia in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Reperfusion-injury in USA
  • 03 Oct 2014 DecImmune receives SBIR phase IIb grant from the US National Institutes of Health for development of its N2-targeted monoclonal therapeutic in vascular inflammatory diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top